Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter randomized open-label study to evaluate safety and anticancer activity of aumolertinib with apatinib for advanced or metastatic NSCLC patients with EGFR mutation

Next Previous
Trial Profile

A multicenter randomized open-label study to evaluate safety and anticancer activity of aumolertinib with apatinib for advanced or metastatic NSCLC patients with EGFR mutation

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 24 Oct 2023 Results (n=104; From Jun. 2021 to Nov. 2022) assessing the efficacy and safety of aumolertinib plus apatinib (AUM + APA) versus aumolertinib (AUM) alone as the first-line therapy for EGFR-mutated NSCLC, presented at the 48th European Society for Medical Oncology Congress.
  • 04 Jul 2022 New trial record
  • 07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top